[Growth hormone-receptor antagonist pegvisomant].
Herrmann
B L
BL
Klinik für Endokrinologie, Zentrum für Innere Medizin, Universitätsklinikum Essen.
Strasburger
C J
CJ
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000236:Adenoma / Q000150:complications / Q000532:radiotherapy / Q000601:surgery; D000328:Adult; D005260:Female; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D009154:Mutation; D010911:Pituitary Neoplasms / Q000150:complications / Q000532:radiotherapy / Q000601:surgery; D011247:Pregnancy; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors* / Q000235:genetics; D012307:Risk Factors; D013997:Time Factors
D011986:Receptors, Somatotropin; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; C406545:pegvisomant